Organigram Global Inc. (Organigram) is a Canadian licensed producer of cannabis and cannabis-derived products for adult-use recreational consumers and medical patients in Canada. The company also has various international business relationships that it continuously seeks to develop in order to expand its global footprint.
On February 27, 2023, the company announced the launch of SHRED X Rip-Strip Hash, which is an extension of the company’s SHRED product portfolio that includes SHRED pre-milled...
Organigram Global Inc. (Organigram) is a Canadian licensed producer of cannabis and cannabis-derived products for adult-use recreational consumers and medical patients in Canada. The company also has various international business relationships that it continuously seeks to develop in order to expand its global footprint.
On February 27, 2023, the company announced the launch of SHRED X Rip-Strip Hash, which is an extension of the company’s SHRED product portfolio that includes SHRED pre-milled flower, SHRED Jar of Joints, SHRED’ems gummies and SHRED X Vapes.
On March 13, 2023, the company announced that Health Canada had determined that certain Edison JOLTS lozenge products in their 100mg THC per package format (the ‘Edison JOLTS Products’) had been improperly classified as a cannabis extract rather than edible cannabis under the Cannabis Regulations. The company launched the Edison JOLTS products in August 2021 following significant research, development and regulatory work.
On March 31, 2023, the company entered into a product purchase agreement (‘Purchase Agreement’) with Greentank and a subscription agreement (the ‘Greentank Subscription Agreement’) with Greentank’s parent company, Weekend Holdings Corp (‘Weekend Holdings’). The Purchase Agreement provided the company with an exclusivity period in Canada for new technology incorporated into 510 vape cartridges (along with other formats) for use with cannabis, including the development of a custom all-in-one device that will be proprietary to the company.
On May 23, 2023, the company had entered into a supply agreement (the ‘Supply Agreement’) for dried flower with the medical division of German cannabis company Sanity Group, a health and life sciences company based in Berlin, Germany, dedicated to the medical applications of cannabinoids. Under the terms of the Supply Agreement, the company will provide high-quality, indoorgrown dried flower product to Sanity Group and grant Sanity Group strain exclusivity on certain genetics.
On May 25, 2023, the company had reached agreement with Phylos, a U.S. cannabis genetics company and provider of production ready seeds, based in Portland, Oregon, to initiate a wideranging technical and commercial relationship in Canada.
On June 21, 2023, the company announced the launch of SHRED X Heavies, a line of innovative infused pre-rolls.
On August 2, 2023, the company announced the launch of its new tube-style pre-rolls, SHRED Dartz and Holy Smokes.
On August 15, 2023, the company entered into a supply agreement to provide dried medical cannabis flower to 4C LABS, a healthcare, technology, and pharmaceutical company focused on virtual prescribing, pharmaceutical distribution, and clinical development of cannabis-based products for human health in the United Kingdom. Pursuant to the terms of the agreement, the company has supplied approximately 288 kilograms of high-quality, indoor-grown dried flower product to 4C LABS to date, less than the initially anticipated 600 kilograms. The company has also granted 4C LABS strain exclusivity within the geographical boundaries of the United Kingdom and Channel Islands for as long as minimum purchase commitments are satisfied under the terms of the agreement.
On November 6, 2023, the company announced a follow-on strategic equity investment from BT DE Investments Inc. (the ‘Investor’), a wholly-owned subsidiary of BAT (the ‘Follow-on BAT Investment’). The majority of the investment will be used by Organigram to create a strategic investment pool, named Jupiter (‘Jupiter’). Jupiter will target investments in emerging cannabis opportunities that will enable the company to apply its industry-leading capabilities to new markets.
On May 28, 2024, the company announced its second international medical cannabis customer in the United Kingdom, Avida Medical Limited (‘Avida’), a full-service medical cannabis and specials medicines manufacturing business. Subject to the terms of the agreement with Avida, the company expects to supply 1,700 kilograms of high quality, indoor-grown dried cannabis flower to Avida in the United Kingdom over a period of three years.
On June 25, 2024, the company announced a strategic investment in Sanity Group, representing its first significant strategic investment aimed at expanding its presence in the European cannabis market.
On November 26, 2024, the company announced the launch of Edison Sonics gummies, Organigram’s inaugural product powered by FAST.
On December 6th, 2024, the company announced the acquisition of 100% of the issued and outstanding shares of Motif.
Principal Products and Brands
The company has established strong brands for use in the adult-use recreational cannabis market and seeks to create a portfolio of diverse brands and products. The company’s adult-use recreational cannabis brand strategy reflects its views about current and potential consumers, the industry, future product development and opportunities for growth.
Adult Use Recreational Cannabis
The company developed its portfolio of adult-use recreational cannabis brands to specifically meet the diverse needs of Canada’s adult-use recreational cannabis consumers. Based on a robust consumer segmentation study, Organigram has and will continue to develop a competitive range of brands designed to deliver profitable growth across the largest product categories. The suite of brands includes SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, Edison Cannabis Co., and Tremblant. Each brand is unique to a specific consumer segment with a product offering designed to meet the needs of its target audience, as described below, including potencies, cannabinoid content and price point.
Medical Cannabis
The company offers a broad range of medical cannabis products in Canada and abroad through the company’s international business partners. The company’s range of products available in the medical channel includes whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies & concentrates.
Distribution and Sales
Adult-Use Recreational Cannabis
The company is authorized by its licence for wholesale distribution of adult-use recreational cannabis and derivative products in all provinces of Canada and in Yukon, and has supply arrangements in different forms with the responsible government agency or equivalent in each province and territory.
Medical Cannabis
The company distributes medical cannabis through MyMedi.ca, an online medical cannabis platform managed by Avicanna Inc. The online medical cannabis platform offers a wide range of medical products and dedicated customer service. The company’s prices for cannabis and derivative products vary based on growth time, strain yield and market prices. The company may from time to time offer volume discount or promotional pricing. The company is also authorized for wholesale shipping of medical cannabis plant cuttings and dried flower to other licensed producers. The company is able to ship wholesale medical cannabis products to certain international jurisdictions by obtaining the required approvals and permits from Health Canada and the applicable regulatory authority of the purchaser.
Cannabis Edibles
Effective October 17, 2019, the Cannabis Regulations permit the sale to the public of edible cannabis products and concentrates through medical and adult-use consumer channels. Following the investment in a high-speed, high-capacity, fully automated production line, the company began shipping edibles to retailers across Canada in February 2020. The company subsequently began evaluating future prospects for its chocolate production line based on its declining utilization and declining revenues from its chocolate output and ultimately made the strategic decision to cease manufacturing chocolate products. Following the acquisition of EIC, the company launched SHRED’ems cannabis-infused gummies and Monjour, a gummy brand focusing on CBD-forward products. The previously-discussed FAST technology developed by the CoE that was announced by the company in August 2024 is anticipated to improve the company’s edible cannabis products by decreasing the average time required for the effects of edible cannabis to be felt by a consumer.
Cannabis Extracts and Concentrates
The company continues to expand its vape offering by having introduced a liquid diamond vape cartridge, as well as Shred 510 vapes featuring distillate and botanical terpene blends. Following the acquisition of LAU, the company established a robust hash innovation pipeline, expanded the Tremblant hash brand nationally via new higher potency hash temple balls, and introduced other new hash products into the market.
Cannabis Vapour Products
In March 2023, Organigram entered into an agreement with Greentank for the development and commercialization of novel vapour heating technology. The company is expecting commercialization to begin in late fiscal year 2025. The Greentank hardware is expected to deliver to the consumer greater vapour volume, stronger flavour and cannabinoid performance through improved and smaller particle size in vapour with their new heating engine.
International Customers
Outside of Canada, the company serves several international markets via exports and seeks to augment sales channels internationally over time. Future international shipments are contingent upon the timing and receipt of regulatory approval from Health Canada, including obtaining an export permit, as well as timing and receipt of regulatory approval from the purchaser's regulatory authority, including obtaining an import permit.
Operations
The company has assembled a capable management team with significant experience in the management and growth of successful enterprises. Presently, a significant portion of the company’s revenue is derived from the sale of cannabis, cannabis product and cannabis plant material produced, cultivated and/or processed by the company at its Moncton Campus. The company grows cannabis at its Moncton Campus for the purposes of sale and distribution of finished products. The Moncton Campus has 115 grow rooms with staggered cultivation cycles averaging 14 weeks per cycle. As the grow rooms are all indoor, seasonality has negligible impact on cultivation cycles.
In July 2022, the company acquired the Winnipeg Facility which it had been previously leasing. EIC held the EIC Licence issued under the Cannabis Act, which was transitioned to be held by OGI as a result of the Amalgamation. The company is producing cannabis-infused gummies and cannabis-infused lozenges at the Winnipeg Facility.
In September 2023, the company completed the expansion of the Lac-Supérieur Facility adding four hybrid greenhouses increasing the cultivation footprint to 14,500 sq. ft. The Lac-Supérieur Facility is destined to produce craft flower with a staggered cultivation cycle averaging 11-12 weeks per cycle as the LacSupérieur Facility receives clones ready for transplant.
Cultivation
The company’s breeding and phenotyping program continues to produce a robust and strategic flower pipeline, with significant progress made to increase the quality, potency and terpene concentrations of the company’s flower portfolio. Several large-scale garden strategies have begun implementation, including start-up of seed based manufacturing, move to segment plant care based on cultivar and portfolio value, and ongoing introduction of improved irrigation practices, specific LED light recipes and crop cycle changes to improve quality output while reducing crop cycle, drying and curing time.
In May 2023, Organigram entered into an innovation agreement with Phylos to develop and operationalize F1 hybrid seed based production, which scaled the company’s production by up to 17% of harvests in FY 2024, significantly reducing the garden cost profile while improving economics on certain milled and ready to consume brands in the portfolio. In addition, Organigram has further capitalized on the investment with the launch of first to market, whole flower THCV offerings in both edible and vapour categories. Organigram expects to expand the offering with further development of a range of novel high potency rare cannabinoids via the proprietary, patent protected cultivation methods developed by Phylos.
History
The company was incorporated under the Business Corporations Act (British Columbia) in 2010. It was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
